Skyclarys (Omaveloxolone) Patent Expiration, LOE Window & CMS Spending

Skyclarys (Omaveloxolone) by Biogen: FDA Orange Book core substance LOE 2033-04-24, 0 AB generics, $175.7M 2024 CMS Part D & Medicaid spend, and $30,833 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBiogen
FDA Application & PathwayN216718 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2033-04-24
Last Listed Patent or Exclusivity Date2033-04-24
Orange Book Patents (*PED Extensions)7 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$175.7M
2024 Medicare Part D Spend$101.3M
2024 Medicaid Spend$74.4M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($30,833 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Biogen across sibling Meru public-data platforms.